RxDoctor Payments Data

Jamee McCarthy, NP

Acute Care · Littleton, CONPI 1447978788

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.

$3,138in general payments, 2019–2025

Across 78 payments — averaging $40.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$533
  • Boston Scientific$532
  • Novartis$438
  • Amgen$317
  • Boehringer Ingelheim$156
  • Novo Nordisk$156
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,138 in reported general payments places this provider in the 85th percentile of 239 acute care providers in Colorado.

See all acute care providers in Colorado

Medicare billing

Part B allowed, 2024
$149,110
Medicare patients
245
Services billed
9,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab453$324,794
OzempicSemaglutide126$134,082
Praluent PenAlirocumab90$62,372
MounjaroTirzepatide58$57,375
WegovySemaglutide26$38,903
NexletolBempedoic Acid15$8,972
Repatha SyringeEvolocumab14$7,655
NexlizetBempedoic Acid/Ezetimibe12$6,938
Ezetimibe96$1,865
Rosuvastatin Calcium147$1,858
Atorvastatin Calcium50$504
FenofibrateFenofibrate Nanocrystallized12$220
Lisinopril11$178
Metoprolol Succinate17$150
Amlodipine Besylate17$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$156$172,985152 claims
Lilly USA, LLCMounjaro$149$57,37558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 239 acute care providers in Colorado.

Other acute care in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →